IBM
The plot thickens
IBM can’t seem to shake the fallout from its July 14 preliminary second-quarter warning. After the stock got clocked by more than 24%, a new shareholder investigation is now asking whether IBM’s upbeat talk about the IBM Z 2026 cycle and the z17 program lined up with reality.
Why investors care
This is the kind of thing that turns a bad quarter into a longer soap opera. The core issue isn’t just weaker revenue and earnings guidance — it’s whether management painted too rosy a picture before the slowdown showed up in the numbers.
That matters because:
- legal probes can invite more headlines, more volatility, and more lawyerly alphabet soup
- they can pressure investor confidence right when a company needs it most
- they often keep a stock stuck in “prove it” mode even after the initial selloff
Big picture
IBM’s AI-and-mainframe comeback story was already taking a punch to the gut from the guidance reset. Now the company gets to deal with the other favorite feature of public markets: when bad earnings news shows up, the lawsuits usually don’t RSVP late — they arrive right on time.